1. Home
  2. RLMD vs CNFR Comparison

RLMD vs CNFR Comparison

Compare RLMD & CNFR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RLMD
  • CNFR
  • Stock Information
  • Founded
  • RLMD 2004
  • CNFR 2009
  • Country
  • RLMD United States
  • CNFR United States
  • Employees
  • RLMD N/A
  • CNFR N/A
  • Industry
  • RLMD Biotechnology: Pharmaceutical Preparations
  • CNFR Property-Casualty Insurers
  • Sector
  • RLMD Health Care
  • CNFR Finance
  • Exchange
  • RLMD Nasdaq
  • CNFR Nasdaq
  • Market Cap
  • RLMD 11.5M
  • CNFR 11.4M
  • IPO Year
  • RLMD N/A
  • CNFR 2015
  • Fundamental
  • Price
  • RLMD $0.30
  • CNFR $0.50
  • Analyst Decision
  • RLMD Hold
  • CNFR
  • Analyst Count
  • RLMD 4
  • CNFR 0
  • Target Price
  • RLMD $4.25
  • CNFR N/A
  • AVG Volume (30 Days)
  • RLMD 382.7K
  • CNFR 21.5K
  • Earning Date
  • RLMD 03-27-2025
  • CNFR 05-13-2025
  • Dividend Yield
  • RLMD N/A
  • CNFR N/A
  • EPS Growth
  • RLMD N/A
  • CNFR N/A
  • EPS
  • RLMD N/A
  • CNFR 1.92
  • Revenue
  • RLMD N/A
  • CNFR $66,771,000.00
  • Revenue This Year
  • RLMD N/A
  • CNFR $24.98
  • Revenue Next Year
  • RLMD N/A
  • CNFR N/A
  • P/E Ratio
  • RLMD N/A
  • CNFR $0.25
  • Revenue Growth
  • RLMD N/A
  • CNFR N/A
  • 52 Week Low
  • RLMD $0.24
  • CNFR $0.45
  • 52 Week High
  • RLMD $5.09
  • CNFR $1.91
  • Technical
  • Relative Strength Index (RSI)
  • RLMD 50.05
  • CNFR 23.50
  • Support Level
  • RLMD $0.26
  • CNFR $0.45
  • Resistance Level
  • RLMD $0.32
  • CNFR $0.68
  • Average True Range (ATR)
  • RLMD 0.02
  • CNFR 0.08
  • MACD
  • RLMD 0.00
  • CNFR -0.02
  • Stochastic Oscillator
  • RLMD 67.34
  • CNFR 14.90

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage biotechnology company. It is engaged in developing chemical entities with novel versions of drug products that address areas of high unmet medical need in the treatment of central nervous system diseases. The company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Its lead product candidate, esmethadone, is an oral agent for the treatment of depression and other potential indications.

About CNFR Conifer Holdings Inc.

Conifer Holdings Inc is an insurance company engaged in the sale of property and casualty insurance products. It is engaged in three classes of insurance businesses namely commercial lines, personal lines, and wholesale agency business. Within these three businesses, the company offers various insurance products and insurance agency services. The company views the commercial and personal lines segments as underwriting business. The wholesale agency business provides non-risk bearing revenue through commissions and policy fees. Its revenues are derived from premiums earned from insurance operations.

Share on Social Networks: